Request Demo
Last update 14 Jun 2025
KD-6001
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Biological products |
Synonyms KD 6001, KD-6001, KD6001 |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with KD-6001NCT05906524
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KD6001 in Combination With Tislelizumab±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
NCT05723432
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
CTR20230746
一项评价 KD6001 注射液联合特瑞普利单抗在晚期黑色素瘤患者中安全性、耐受性、药代动力学和初步疗效的临床研究
[Translation] A clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of KD6001 injection combined with toripalimab in patients with advanced melanoma
100 Clinical Results associated with KD-6001
Login to view more data
100 Translational Medicine associated with KD-6001
Login to view more data
100 Patents (Medical) associated with KD-6001
Login to view more data
100 Deals associated with KD-6001
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatocellular Carcinoma | Phase 2 | China | - | 15 Apr 2024 |
| Liver Cancer | Phase 2 | China | 13 Jul 2023 | |
| Melanoma | Phase 2 | China | 14 Mar 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 10 Sep 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 29 | qzeqdefuju(qnvjebvmga) = hkyfjcvpst nvczmzdzmg (msyjamqoyt ) View more | Positive | 24 May 2024 | |||
KD6001 + toripalimab (without brain metastases) | nfqzighvrl(tmvopjfnhb) = inlapwcnnb vvllhwzeox (kqqkiwcray ) View more | ||||||
NCT05230290 (ASCO2024) Manual  | Phase 1 | 13 | KD6001 3mg/kg | cxtrijvcxu(gjrvwavmea) = Not observed. tzlcbzhvlp (zdyirjiavk ) View more | Positive | 24 May 2024 | |
KD6001 0.2,1,3,6mg/kg |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free